Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
For young patients with high-risk CLL, BTK-/PI3K-inhibitors or allogeneic stem cell transplantation (alloHCT) are considered. Patients with a low risk of non-relapse mortality (NRM) but a high risk of failure of targeted therapy may benefit most from alloHCT. We performed Cox regression analyses to...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 January 2017
|
| In: |
Bone marrow transplantation
Year: 2017, Jahrgang: 52, Heft: 4, Pages: 552-560 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/bmt.2016.329 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/bmt.2016.329 Verlag, Volltext: https://www.nature.com/articles/bmt2016329 
|
| Verfasserangaben: | J. Schetelig, L.C. de Wreede, M. van Gelder, N.S. Andersen, C. Moreno, A. Vitek, M. Karas, M. Michallet, M. Machaczka, M. Gramatzki, D. Beelen, J. Finke, J. Delgado, L. Volin, J. Passweg, P. Dreger, A. Henseler, A. van Biezen, M. Bornhäuser, S. O. Schönland and N. Kröger on behalf of the CLL subcommittee, Chronic Malignancies Working Party |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572257458 | ||
| 003 | DE-627 | ||
| 005 | 20230426124252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180423s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bmt.2016.329 |2 doi | |
| 035 | |a (DE-627)1572257458 | ||
| 035 | |a (DE-576)502257458 | ||
| 035 | |a (DE-599)BSZ502257458 | ||
| 035 | |a (OCoLC)1341007406 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schetelig, Johannes |d 1968- |e VerfasserIn |0 (DE-588)120026953 |0 (DE-627)696313138 |0 (DE-576)292002831 |4 aut | |
| 245 | 1 | 0 | |a Risk factors for treatment failure after allogeneic transplantation of patients with CLL |b a report from the European Society for Blood and Marrow Transplantation |c J. Schetelig, L.C. de Wreede, M. van Gelder, N.S. Andersen, C. Moreno, A. Vitek, M. Karas, M. Michallet, M. Machaczka, M. Gramatzki, D. Beelen, J. Finke, J. Delgado, L. Volin, J. Passweg, P. Dreger, A. Henseler, A. van Biezen, M. Bornhäuser, S. O. Schönland and N. Kröger on behalf of the CLL subcommittee, Chronic Malignancies Working Party |
| 264 | 1 | |c 23 January 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.04.2018 | ||
| 520 | |a For young patients with high-risk CLL, BTK-/PI3K-inhibitors or allogeneic stem cell transplantation (alloHCT) are considered. Patients with a low risk of non-relapse mortality (NRM) but a high risk of failure of targeted therapy may benefit most from alloHCT. We performed Cox regression analyses to identify risk factors for 2-year NRM and 5-year event-free survival (using EFS as a surrogate for long-term disease control) in a large, updated EBMT registry cohort (n= 694). For the whole cohort, 2-year NRM was 28% and 5-year EFS 37%. Higher age, lower performance status, unrelated donor type and unfavorable sex-mismatch had a significant adverse impact on 2-year NRM. Two-year NRM was calculated for good- and poor-risk reference patients. Predicted 2-year-NRM was 11 and 12% for male and female good-risk patients compared with 42 and 33% for male and female poor-risk patients. For 5-year EFS, age, performance status, prior autologous HCT, remission status and sex-mismatch had a significant impact, whereas del(17p) did not. The model-based prediction of 5-year EFS was 55% and 64%, respectively, for male and female good-risk patients. Good-risk transplant candidates with high-risk CLL and limited prognosis either on or after failure of targeted therapy should still be considered for alloHCT. | ||
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 52(2017), 4, Seite 552-560 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Risk factors for treatment failure after allogeneic transplantation of patients with CLL a report from the European Society for Blood and Marrow Transplantation |
| 773 | 1 | 8 | |g volume:52 |g year:2017 |g number:4 |g pages:552-560 |g extent:9 |a Risk factors for treatment failure after allogeneic transplantation of patients with CLL a report from the European Society for Blood and Marrow Transplantation |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/bmt.2016.329 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/bmt2016329 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180423 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 16 | ||
| 999 | |a KXP-PPN1572257458 |e 3006895770 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"title":[{"title_sort":"Bone marrow transplantation","title":"Bone marrow transplantation"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2017","extent":"9","issue":"4","volume":"52","pages":"552-560","text":"52(2017), 4, Seite 552-560"},"language":["eng"],"id":{"eki":["320433366"],"zdb":["2004030-1"],"issn":["1476-5365"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"London ; Basingstoke ; London","dateIssuedDisp":"1997-","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group","dateIssuedKey":"1997"}],"pubHistory":["Nachgewiesen 19.1997 -"],"note":["Gesehen am 17.01.25"],"recId":"320433366","disp":"Risk factors for treatment failure after allogeneic transplantation of patients with CLL a report from the European Society for Blood and Marrow TransplantationBone marrow transplantation"}],"physDesc":[{"extent":"9 S."}],"person":[{"role":"aut","family":"Schetelig","display":"Schetelig, Johannes","given":"Johannes"},{"role":"aut","display":"Dreger, Peter","family":"Dreger","given":"Peter"}],"title":[{"title_sort":"Risk factors for treatment failure after allogeneic transplantation of patients with CLL","title":"Risk factors for treatment failure after allogeneic transplantation of patients with CLL","subtitle":"a report from the European Society for Blood and Marrow Transplantation"}],"origin":[{"dateIssuedDisp":"23 January 2017","dateIssuedKey":"2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1038/bmt.2016.329"],"eki":["1572257458"]},"language":["eng"],"recId":"1572257458","note":["Gesehen am 23.04.2018"],"name":{"displayForm":["J. Schetelig, L.C. de Wreede, M. van Gelder, N.S. Andersen, C. Moreno, A. Vitek, M. Karas, M. Michallet, M. Machaczka, M. Gramatzki, D. Beelen, J. Finke, J. Delgado, L. Volin, J. Passweg, P. Dreger, A. Henseler, A. van Biezen, M. Bornhäuser, S. O. Schönland and N. Kröger on behalf of the CLL subcommittee, Chronic Malignancies Working Party"]}} | ||
| SRT | |a SCHETELIGJRISKFACTOR2320 | ||